1. Scrip
  2. >>Business
  3. >>Strategy

Alkermes Ready To More Aggressively Pursue Deals After Oncology Spin-Out

Mural Oncology Launched In November

 
• By Mandy Jackson

After Alkermes spun out its oncology assets into a separate public entity so the company could focus exclusively on neuroscience, CEO Richard Pops said it will look externally to build its pipeline.

Human brain activity with plexus lines. External cerebral connections in the frontal lobe.
Alkermes is focused entirely on central nervous system diseases going forward • Source: Shutterstock

Now that Alkermes plc has completed the spin out of its oncology business as a separately traded public company, Mural Oncology plc, the neuroscience-focused firm is prepared to be a more active dealmaker as it further builds out its research and development pipeline, CEO Richard Pops told Scrip in an interview during the recent J.P. Morgan Healthcare Conference in San Francisco.

“We’ll be more aggressive now,” Pops said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

How Much Does Biopharma Contributes To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

More from Conferences